GlaxoSmithKline PLC
LSE:GSK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GlaxoSmithKline PLC
Free Cash Flow
GlaxoSmithKline PLC
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
GlaxoSmithKline PLC
LSE:GSK
|
Free Cash Flow
£4.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
22%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Free Cash Flow
$8.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
32%
|
CAGR 10-Years
32%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Free Cash Flow
$119m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-6%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Free Cash Flow
-£36.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-22%
|
|
|
Animalcare Group PLC
LSE:ANCR
|
Free Cash Flow
£8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
10%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Free Cash Flow
£37.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
GlaxoSmithKline PLC
Glance View
Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.
See Also
What is GlaxoSmithKline PLC's Free Cash Flow?
Free Cash Flow
4.8B
GBP
Based on the financial report for Dec 31, 2025, GlaxoSmithKline PLC's Free Cash Flow amounts to 4.8B GBP.
What is GlaxoSmithKline PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
22%
Over the last year, the Free Cash Flow growth was 33%. The average annual Free Cash Flow growth rates for GlaxoSmithKline PLC have been -3% over the past three years , -5% over the past five years , and 22% over the past ten years .